This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 7 of 7 for:    "alba therapeutics"

Safety and Tolerability Study of AT1001 in Celiac Disease Subjects

This study has been completed.
Information provided by:
Alba Therapeutics Identifier:
First received: August 8, 2006
Last updated: November 12, 2007
Last verified: February 2007

There are no therapeutic products on the market for celiac disease today. Current treatment is limited to gluten free foods and a gluten-free diet.

The main purpose of this study is to test how safe, efficacious and tolerable the study drug AT1001 is in subjects with diagnosed celiac disease.

A second purpose is to study how your body responds to the drug when you ingest gluten. This response is determined by testing your urine, and by capturing your daily and weekly gastrointestinal symptoms associated with celiac disease.

Condition Intervention Phase
Celiac Disease Drug: AT1001 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of AT-1001 in Celiac Disease Subjects During Gluten Challenge.

Resource links provided by NLM:

Further study details as provided by Alba Therapeutics:

Primary Outcome Measures:
  • To demonstrate the safety and tolerability of multiple, oral doses of AT-1001 in celiac disease subjects that maintain a gluten-free diet.

Secondary Outcome Measures:
  • To evaluate the efficacy of multiple dose levels of AT-1001 in preventing intestinal permeability changes induced by gluten challenge
  • to evaluate the effects of multiple dose levels of AT-1001 in preventing the induction of celiac disease signs and symptoms resulting from gluten challenge.

Estimated Enrollment: 79
Study Start Date: August 2006
Study Completion Date: March 2007

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have been diagnosed with celiac disease by biopsy for ≥ 6 months (attending physician confirmation will be accepted in lieu of a biopsy report).
  • Have a Anti-Tissue Transglutaminase (tTG) ≤ 10 EU as measured by serology.
  • Must be on a gluten-free diet for at least the past 6 months.

Exclusion Criteria:

  • Have any chronic active GI disease other than celiac disease (e.g., IBS, Crohn's, Colitis).
  • Have diabetes (Type 1 or Type 2).
  • Chronically consumes non-steroidal anti-inflammatory agents ("NSAIDs") or takes proton-pump inhibitors.
  • Consuming oral corticosteroids or immune suppressants.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00362856

United States, Arizona
Research Site
Scottsdale, Arizona, United States, 85259
United States, California
San Diego, California, United States, 92123
United States, Massachusetts
Research Site
Boston, Massachusetts, United States, 02215
United States, Minnesota
Research Site
Rochester, Minnesota, United States, 55905
United States, New Jersey
Morristown, New Jersey, United States, 07960
United States, North Dakota
Bismarck, North Dakota, United States, 58501
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19107
Pittsburgh, Pennsylvania, United States, 15241
United States, Virginia
Research Site
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Alba Therapeutics
  More Information Identifier: NCT00362856     History of Changes
Other Study ID Numbers: CLIN1001-004
Study First Received: August 8, 2006
Last Updated: November 12, 2007

Additional relevant MeSH terms:
Celiac Disease
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Metabolic Diseases processed this record on August 18, 2017